...
首页> 外文期刊>The lancet oncology >Natural history of cervical neoplasia and risk of invasive cancer in women with cervical intraepithelial neoplasia 3: a retrospective cohort study.
【24h】

Natural history of cervical neoplasia and risk of invasive cancer in women with cervical intraepithelial neoplasia 3: a retrospective cohort study.

机译:宫颈上皮内瘤变妇女的宫颈癌自然史和浸润癌风险:一项回顾性队列研究。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

BACKGROUND: The invasive potential of cervical intraepithelial neoplasia 3 (CIN3; also termed stage 0 carcinoma) has been poorly defined. At the National Women's Hospital, Auckland, New Zealand, treatment of CIN3 was withheld from a substantial number of women between 1965 and 1974 as part of an unethical clinical study. The resulting variation in management allows comparison of the long-term risk of invasive cancer of the cervix in women whose lesion was minimally disturbed with those who had adequate initial treatment followed by conventional management. We aimed to estimate the long-term risk of invasive cancer in these two groups of women. A judicial inquiry referred for independent clinical review in 1988 all women for whom there remained doubt about the adequacy of their management. METHODS: Between February, 2001, and December, 2004, medical records, cytology, and histopathology were reviewed for all women with CIN3 diagnosed between 1955 and 1976, whose treatment was reviewed by judicial inquiry and whose medical records could be located, and linkages were done with cancer and death registers and electoral rolls. To take into account the probability that the CIN3 lesion had been completely removed, we classified adequacy of treatment by type of procedure, presence of CIN3 at the excision margin, and subsequent cytology. The primary outcome was cumulative incidence of invasive cancer of the cervix or vaginal vault. Follow-up continued until death or Dec 31, 2000, whichever came first. Analyses accounted for procedures during follow-up. FINDINGS: 1229 women whose treatment was reviewed by the judicial inquiry in 1987-88 were included. Of these, 48 records (4%) could not be located and 47 women (4%) did not meet the inclusion criteria. At histopathological review, a further 71 (6% of 1134) women were excluded because the review diagnosis was not CIN3. We identified outcomes in the remaining 1063 (86% of 1229) women diagnosed with CIN3 at the hospital in 1955-76. In 143 women managed only by punch or wedge biopsy, cumulative incidence of invasive cancer of the cervix or vaginal vault was 31.3% (95% CI 22.7-42.3) at 30 years, and 50.3% (37.3-64.9) in the subset of 92 such women who had persistent disease within 24 months. However, cancer risk at 30 years was only 0.7% (0.3-1.9) in 593 women whose initial treatment was deemed adequate or probably adequate, and whose treatment for recurrent disease was conventional. INTERPRETATION: This study provides the most valid direct estimates yet available of the rate of progression from CIN3 to invasive cancer. Women with untreated CIN3 are at high risk of cervical cancer, whereas the risk is very low in women treated conventionally throughout.
机译:背景:宫颈上皮内瘤变3(CIN3;也称为0期癌)的侵入潜力尚未明确。 1965年至1974年之间,在新西兰奥克兰的国家妇女医院中,由于不道德临床研究的一部分,许多妇女都停止了CIN3的治疗。由此产生的管理差异可比较病灶受轻微影响的妇女与经过适当初始治疗后再常规治疗的妇女的宫颈浸润癌的长期风险。我们旨在评估这两组妇女的浸润性癌症的长期风险。 1988年的一项司法调查要求对所有对其管理是否足够存有疑问的妇女进行独立的临床审查。方法:在2001年2月至2004年12月之间,对所有1955年至1976年诊断为CIN3的女性进行了病历,细胞学和组织病理学检查,并通过司法调查对他们的治疗进行了回顾,并且可以找到其病历,并且建立了联系。完成了癌症和死亡登记册以及选举名册。考虑到CIN3病变已被完全清除的可能性,我们按手术类型,切除边缘处CIN3的存在以及随后的细胞学分类对治疗的适当性进行了分类。主要结果是宫颈或阴道穹ault浸润性癌的累积发生率。随访一直持续到死亡或2000年12月31日,以先到者为准。随访过程中分析了程序。结果:包括1229名妇女,她们的治疗方法在1987-88年通过司法调查得到了审查。在这些记录中,找不到48条记录(占4%),而47名妇女(占4%)不符合纳入标准。在组织病理学检查中,又有71名妇女(占1134%)被排除在外,因为该检查诊断不是CIN3。我们在1955-76年间在医院诊断为CIN3的其余1063名妇女(占1229%的女性)中确定了结局。在仅通过打孔或楔形活检处理的143名妇女中,在30岁时宫颈或阴道穹ault浸润性癌的累积发生率是31.3%(95%CI 22.7-42.3),在92个子集中是50.3%(37.3-64.9)这类妇女在24个月内患有持续性疾病。但是,在593名最初治疗被认为适当或可能适当并且常规治疗复发的妇女中,30岁时的癌症风险仅为0.7%(0.3-1.9)。解释:这项研究提供了从CIN3到浸润性癌症进展速度的最有效的直接估计。未经治疗的CIN3妇女罹患宫颈癌的风险很高,而在整个过程中常规接受治疗的妇女的风险非常低。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号